Overview

A Phase II Study of Selinexor Plus Cytarabine and Idarubicin in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)

Status:
Completed

Trial end date:
2018-07-31

Target enrollment:

Participant gender:

Summary

Acute Myeloid Leukemia (AML) is currently treated with chemotherapy by combining several drugs with different ways of inhibiting the cell growth. In this trial, standard chemotherapeutics that have proven their effectiveness for years, Ara-C and Idarubicin, will be combined with a new drug called Selinexor. Selinexor inhibits the growth of cancer cells by keeping certain proteins in the nucleus which control the cell growth.

Phase:

Phase 2

Details

Lead Sponsor:

GSO Global Clinical Research BV

Collaborators:

Karyopharm Therapeutics Inc
Karyopharm Therapeutics, Inc

Treatments:

Cytarabine
Idarubicin